AbbVie

NCT07793422

Phase 3Not yet recruiting370 people28 Aug 2026clinicaltrials.gov

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Phase 2Recruiting360 people7 Aug 2026clinicaltrials.gov

NCT07744126

Phase 2Recruiting150 people4 Aug 2026clinicaltrials.gov

NCT07728188

Phase 3Not yet recruiting520 people27 Jul 2026clinicaltrials.gov

NCT07600151

CollaboratorPhase 1/2Not yet recruiting220 people20 May 2026clinicaltrials.gov

NCT07567781

Phase 1Completed12 people5 May 2026clinicaltrials.gov

NCT07175415

CollaboratorPhase 1/2Not yet recruiting42 people16 Sept 2025clinicaltrials.gov

NCT07097363

CollaboratorPhase 2Recruiting18 people31 Jul 2025clinicaltrials.gov

NCT07095452

Phase 2/3Recruiting680 people31 Jul 2025clinicaltrials.gov

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Phase 2/3Recruiting854 people5 Jun 2025clinicaltrials.gov

NCT06953960

Phase 1/2Recruiting325 people1 May 2025clinicaltrials.gov

NCT06892522

Phase 1/2Recruiting602 people24 Mar 2025clinicaltrials.gov

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Phase 1/2Recruiting252 people13 Jan 2025clinicaltrials.gov

NCT06390319

CollaboratorPhase 2Recruiting100 people30 Apr 2024clinicaltrials.gov

NCT06236438

Phase 2/3Recruiting840 people1 Feb 2024clinicaltrials.gov

NCT06191744

CollaboratorPhase 3Active, not recruiting1,095 people5 Jan 2024clinicaltrials.gov

NCT06158841

Phase 3Active, not recruiting421 people6 Dec 2023clinicaltrials.gov

NCT06093503

Phase 3Withdrawn0 people23 Oct 2023clinicaltrials.gov

A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects

CollaboratorPhase 1Completed12 people10 Mar 2023clinicaltrials.gov

NCT05564650

CollaboratorPhase 1Completed6 people3 Oct 2022clinicaltrials.gov